Bertil Jonsson

Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden — Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials

Luca Pani, Spiros Vamvakas, Eric Abadie, 2011, European Neuropsychopharmacology.

Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities

Gideon Blumenthal, Robert Justice, Francesco Pignatti, 2015, Molecular oncology.

The European Medicines Agency (EMEA) guideline on oncology drug development

Jonas Bergh, S. W. Hansen, Bertil Jonsson, 2007 .